Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 34.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,058 shares of the biopharmaceutical company's stock after selling 35,723 shares during the period. Snowden Capital Advisors LLC's holdings in Bristol-Myers Squibb were worth $3,906,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in BMY. Norges Bank purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $1,989,525,000. Ameriprise Financial Inc. grew its stake in shares of Bristol-Myers Squibb by 59.9% in the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after buying an additional 12,011,983 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Bristol-Myers Squibb by 701.2% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock valued at $705,309,000 after buying an additional 10,913,708 shares during the period. Wellington Management Group LLP boosted its position in shares of Bristol-Myers Squibb by 3,880.0% during the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock worth $338,088,000 after purchasing an additional 5,827,317 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $257,618,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Jefferies Financial Group lowered their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Citigroup increased their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Up 1.3%

NYSE:BMY traded up $0.62 during midday trading on Tuesday, hitting $47.84. 12,593,561 shares of the company were exchanged, compared to its average volume of 13,228,862. The company has a fifty day simple moving average of $52.80 and a 200 day simple moving average of $55.94. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a market capitalization of $97.36 billion, a PE ratio of -10.82, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the firm earned ($4.40) earnings per share. The firm's revenue was down 5.6% on a year-over-year basis. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.18%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.